Biocon is currently trading at Rs. 394.00, up by 27.35 points or 7.46% from its previous closing of Rs. 366.65 on the BSE.
The scrip opened at Rs. 388.75 and has touched a high and low of Rs. 399.50 and Rs. 385.00 respectively. So far 1,90,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 399.50 on 14-Jul-2017 and a 52 week low of Rs. 229.44 on 19-Jul-2016.
Last one week high and low of the scrip stood at Rs. 399.50 and Rs. 305.00 respectively. The current market cap of the company is Rs. 23,787.00 crore.
The promoters holding in the company stood at 60.68%, while Institutions and Non-Institutions held 21.43% and 17.89% respectively.
The US Food and Drug Administration (USFDA) Oncologic Drugs Advisory Committee (ODAC) has unanimously recommended approval of Mylan and Biocon’s Proposed Biosimilar Trastuzumab. The committee voted 16-0 in support of eligible indications of the reference product, Herceptin, which include HER2-positive breast cancer in the metastatic and adjuvant settings.
Mylan and Biocon’s proposed biosimilar trastuzumab is also under review by regulatory authorities in Australia, Canada, Europe and several emerging markets.
Mylan and Biocon are exclusive partners on a broad portfolio of biosimilar and insulin products. The proposed biosimilar trastuzumab is one of the six biologic products co-developed by Mylan and Biocon for the global marketplace.
